Studies have shown that, in patients with type 2 diabetes mellitus, NLRP3 inflammasomes were up-regulated, and metformin treatment modulated the activation of these inflammasomes [32]. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.